Stoke Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Stoke Therapeutics, Inc. had return on equity of -2.4%, an operating margin of -11.2%, debt equal to 0.0% of equity and a current ratio of 5.28. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Stoke Therapeutics, Inc.: financial ratios, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Operating margin	−841.2%	<−999%	−277.3%	−11.2%	−809.7%
Net margin	−814.7%	<−999%	−243.4%	−3.7%	−753.6%
Free-cash-flow margin	−288.8%	−941.7%	−238.1%	24.4%	−654.9%
Return on equity	−54.7%	−60.8%	−45.8%	−2.4%	−59.6%
Return on assets	−39.5%	−43.2%	−35.6%	−2.0%	−51.2%
Asset turnover	0.05	0.04	0.15	0.53	0.07
Current ratio	7.77	6.99	5.81	5.28	7.69
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	n/m	n/m	n/m	n/m
R&D as % of revenue	627.5%	936.6%	243.8%	74.8%	611.0%
SG&A as % of revenue	—	—	133.5%	36.4%	298.7%
Capital spending as % of revenue	31.9%	18.4%	0.6%	0.4%	9.8%

US$ thousands unless shown otherwise. Fiscal quarters.

Stoke Therapeutics, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Operating margin	−613.1%	−60.4%	70.2%	−197.6%	−405.3%	<−999%	−857.6%	−701.7%
Net margin	−540.0%	−46.4%	71.2%	−170.0%	−360.7%	<−999%	−802.7%	−660.8%
Free-cash-flow margin	−443.8%	−102.7%	83.0%	−185.1%	−286.9%	<−999%	−978.2%	−628.0%
Current ratio	5.09	5.81	8.41	6.98	6.53	5.28	8.99	7.69
R&D as % of revenue	453.7%	103.6%	20.6%	187.1%	354.6%	>999%	636.9%	530.8%
SG&A as % of revenue	259.3%	56.8%	9.2%	110.5%	150.7%	>999%	320.7%	270.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026

What it owns · $394m

Short-term assets $323mLonger-term assets $71m

What it owes, and who funded it · $394m

Short-term liabilities $42mLonger-term liabilities $6mShareholders' equity $346m

Short-term assets cover short-term liabilities $323m of assets due within a year against $42m of liabilities due within a year.
Short-term assets cover long-term liabilities $323m short-term assets against $6m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$223m against $46,000 of interest.

From Stoke Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: GLUE vs STOK STOK vs TNXP ARCT vs STOK ABEO vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Stoke Therapeutics, Inc.